Status:
COMPLETED
FQ Restriction for the Prevention of CDI
Lead Sponsor:
University of Wisconsin, Madison
Collaborating Sponsors:
Agency for Healthcare Research and Quality (AHRQ)
Conditions:
Clostridium Difficile
Clostridium Difficile Infection
Eligibility:
All Genders
Brief Summary
This study evaluates the effectiveness of a new intervention, fluoroquinolone (FQ) Preprescription Authorization (PPA) strategy, to reduce and prevent Clostridium difficile infection (CDI) in hospital...
Detailed Description
The objective of the proposed study is to evaluate the effectiveness and implementation of a fluoroquinolone (FQ) Preprescription Authorization (PPA) as an antibiotic stewardship (AS) strategy to targ...
Eligibility Criteria
Inclusion
- Medical-surgical intensive care unit with at least 10 beds
- Presence of existing antibiotic stewardship (AS) program with pharmacist and ID physician support
- Electronic health record (EHR) vendor is Epic Systems Corporation
- Has ability to extract antibiotic usage data (days of therapy)
- Has ability to extract required outcomes data (CDI, mortality, length of ICU stay)
- Ability to extract or abstract data on indications for antibiotic use
- Adherence to best practices for infection control relevant to CDI
Exclusion
- Medical-surgical intensive care units with a FQ restriction in place as part of their usual care procedures will be excluded.
Key Trial Info
Start Date :
May 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2024
Estimated Enrollment :
5871 Patients enrolled
Trial Details
Trial ID
NCT03848689
Start Date
May 1 2019
End Date
May 31 2024
Last Update
January 31 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo-Arizona
Phoenix, Arizona, United States, 85054
2
Riverside University Health System Medical Center
Moreno Valley, California, United States, 92555
3
Mayo-Rochester
Rochester, Minnesota, United States, 55905
4
St. Luke's Health System
Kansas City, Missouri, United States, 64112